Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
Auditor change
Vaxart, Inc. (VXRT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: " "
07/26/2023 8-K Quarterly results
07/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "_PRESS RELEASE JULY 6, 2023"
07/07/2023 SC 13G/A BlackRock Inc. reports a 1.3% stake in Vaxart, Inc.
06/28/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
06/08/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between Vaxart, Inc. and Cantor Fitzgerald & Co",
"Opinion of Thompson Hine LLP",
"Vaxart, Inc. Announces Proposed Public Offering of Common Stock",
"Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock"
06/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results"
05/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 8-K Quarterly results
03/17/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/15/2023 10-K Annual Report for the period ended December 31, 2022
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.4% stake in Vaxart Inc.
01/10/2023 SC 13G/A STATE STREET CORP reports a 1.8% stake in EXIT FILING VAXART INC
12/19/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
10/21/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/01/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate",
"Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer"
08/25/2022 8-K Resignation/termination of a director, Appointed a new director
Docs: "Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors"
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
08/05/2022 8-K/A Quarterly results
07/28/2022 8-K Quarterly results
07/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy